Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Rizatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 May 2009 Results reported in Headache.
- 18 Apr 2009 Patient numbers amended from 196 to 207 as reported by ClinicalTrials.gov.
- 25 Feb 2009 Actual patient numbers (196) added as reported by ClinicalTrials.gov.